Global Calcineurin Inhibitors Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Calcineurin Inhibitors can be defined as immunosuppressants (drugs or medicines that lower the body's ability to reject a transplanted organ) used to manage autoimmune conditions such as lupus nephritis, idiopathic inflammatory myositis, interstitial lung disease, atopic and dermatitis among others. Growing prevalence of prevalence of psoriasis and increasing cases of organ transplant as well as recent product launches from leading market players are key drivers for growth of Calcineurin Inhibitors Market. For instance, according to Global Psoriasis Atlas - as of 2021, around 60 million people are suffering from psoriasis worldwide. Furthermore, in USA around 3.65 million people are affected with psoriasis, whereas in UK around 1.01 million have psoriasis. Moreover, in December 2020, Biopharmaceuticals company Biocon launched Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients. Also, growing number of research and development activities and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, side effects associated with calcineurin inhibitors impede the growth of the market over the forecast period of 2022-2028.
The key regions considered for the global Calcineurin Inhibitors Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of atopic dermatitis as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing healthcare sector and increasing penetration of global pharmaceuticals companies in the region, would create lucrative growth prospects for the Calcineurin Inhibitors Market across the Asia Pacific region.
Major market players included in this report are:
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
AstraZeneca (U.K.)
Johnson & Johnson (U.S.)
Bayer AG (Germany)
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Diseases
Atopic Dermatitis
Postoperative Immunosuppression
Ulcerative Colitis
Psoriasis
Keratoconjunctivitis
Others
By Drug
Cyclosporine
Tacrolimus
Pimecrolimus
Others
By Route of Administration
Oral
Topical
Parenteral
By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028
Target Audience of the Global Calcineurin Inhibitors Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
- 1.2.1. Global Calcineurin Inhibitors Market, by Region, 2020-2028 (USD Million)
- 1.2.2. Global Calcineurin Inhibitors Market, by Diseases, 2020-2028 (USD Million)
- 1.2.3. Global Calcineurin Inhibitors Market, by Drug, 2020-2028 (USD Million)
- 1.2.4. Global Calcineurin Inhibitors Market, by Route of Administration, 2020-2028 (USD Million)
- 1.2.5. Global Calcineurin Inhibitors Market, by End-Users, 2020-2028 (USD Million)
- 1.2.6. Global Calcineurin Inhibitors Market, by Distribution Channel, 2020-2028 (USD Million)
- 1.2.7.
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Calcineurin Inhibitors Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Calcineurin Inhibitors Market Dynamics
- 3.1. Calcineurin Inhibitors Market Impact Analysis (2020-2028)
- 3.1.1. Market Drivers
- 3.1.1.1. Growing prevalence of prevalence of psoriasis.
- 3.1.1.2. Increasing cases of organ transplant.
- 3.1.1.3. Recent product launches from leading Market players.
- 3.1.2. Market Challenges
- 3.1.2.1. Side effects associated with calcineurin inhibitors.
- 3.1.2.2.
- 3.1.3. Market Opportunities
- 3.1.3.1. Growing number of research and development activities
- 3.1.3.2. Rising healthcare infrastructure in emerging economies.
Chapter 4. Global Calcineurin Inhibitors Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
- 4.2. PEST Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.3. Investment Adoption Model
- 4.4. Analyst Recommendation & Conclusion
- 4.5. Top investment opportunity
- 4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1.1. Assessment of the overall impact of COVID-19 on the industry
- 5.1.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Calcineurin Inhibitors Market, by Diseases
- 6.1. Market Snapshot
- 6.2. Global Calcineurin Inhibitors Market by Diseases, Performance - Potential Analysis
- 6.3. Global Calcineurin Inhibitors Market Estimates & Forecasts by Diseases 2018-2028 (USD Million)
- 6.4. Calcineurin Inhibitors Market, Sub Segment Analysis
- 6.4.1. Atopic Dermatitis
- 6.4.2. Postoperative Immunosuppression
- 6.4.3. Ulcerative Colitis
- 6.4.4. Psoriasis
- 6.4.5. Keratoconjunctivitis
- 6.4.6. Others
Chapter 7. Global Calcineurin Inhibitors Market, by Drug
- 7.1. Market Snapshot
- 7.2. Global Calcineurin Inhibitors Market by Drug, Performance - Potential Analysis
- 7.3. Global Calcineurin Inhibitors Market Estimates & Forecasts by Drug 2018-2028 (USD Million)
- 7.4. Calcineurin Inhibitors Market, Sub Segment Analysis
- 7.4.1. Cyclosporine
- 7.4.2. Tacrolimus
- 7.4.3. Pimecrolimus
- 7.4.4. Others
Chapter 8. Global Calcineurin Inhibitors Market, by Route of Administration
- 8.1. Market Snapshot
- 8.2. Global Calcineurin Inhibitors Market by Route of Administration, Performance - Potential Analysis
- 8.3. Global Calcineurin Inhibitors Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)
- 8.4. Calcineurin Inhibitors Market, Sub Segment Analysis
- 8.4.1. Oral
- 8.4.2. Topical
- 8.4.3. Parenteral
Chapter 9. Global Calcineurin Inhibitors Market, by End-Users
- 9.1. Market Snapshot
- 9.2. Global Calcineurin Inhibitors Market by End-Users, Performance - Potential Analysis
- 9.3. Global Calcineurin Inhibitors Market Estimates & Forecasts by End-Users 2018-2028 (USD Million)
- 9.4. Calcineurin Inhibitors Market, Sub Segment Analysis
- 9.4.1. Hospitals
- 9.4.2. Specialty Clinics
- 9.4.3. Homecare
- 9.4.4. Others
Chapter 10. Global Calcineurin Inhibitors Market, by Distribution Channel
- 10.1. Market Snapshot
- 10.2. Global Calcineurin Inhibitors Market by Distribution Channel, Performance - Potential Analysis
- 10.3. Global Calcineurin Inhibitors Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
- 10.4. Calcineurin Inhibitors Market, Sub Segment Analysis
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Online Pharmacy
- 10.4.4. Others
Chapter 11. Global Calcineurin Inhibitors Market, Regional Analysis
- 11.1. Calcineurin Inhibitors Market, Regional Market Snapshot
- 11.2. North America Calcineurin Inhibitors Market
- 11.2.1. U.S. Calcineurin Inhibitors Market
- 11.2.1.1. Diseases estimates & forecasts, 2018-2028
- 11.2.1.2. Drug estimates & forecasts, 2018-2028
- 11.2.1.3. Route of Administration estimates & forecasts, 2018-2028
- 11.2.1.4. End-Users estimates & forecasts, 2018-2028
- 11.2.1.5. Distribution Channel estimates & forecasts, 2018-2028
- 11.2.2. Canada Calcineurin Inhibitors Market
- 11.3. Europe Calcineurin Inhibitors Market Snapshot
- 11.3.1. U.K. Calcineurin Inhibitors Market
- 11.3.2. Germany Calcineurin Inhibitors Market
- 11.3.3. France Calcineurin Inhibitors Market
- 11.3.4. Spain Calcineurin Inhibitors Market
- 11.3.5. Italy Calcineurin Inhibitors Market
- 11.3.6. Rest of Europe Calcineurin Inhibitors Market
- 11.4. Asia-Pacific Calcineurin Inhibitors Market Snapshot
- 11.4.1. China Calcineurin Inhibitors Market
- 11.4.2. India Calcineurin Inhibitors Market
- 11.4.3. Japan Calcineurin Inhibitors Market
- 11.4.4. Australia Calcineurin Inhibitors Market
- 11.4.5. South Korea Calcineurin Inhibitors Market
- 11.4.6. Rest of Asia Pacific Calcineurin Inhibitors Market
- 11.5. Latin America Calcineurin Inhibitors Market Snapshot
- 11.5.1. Brazil Calcineurin Inhibitors Market
- 11.5.2. Mexico Calcineurin Inhibitors Market
- 11.6. Rest of The World Calcineurin Inhibitors Market
Chapter 12. Competitive Intelligence
- 12.1. Top Market Strategies
- 12.2. Company Profiles
- 12.2.1. F. Hoffmann-La Roche Ltd. (Switzerland)
- 12.2.1.1. Key Information
- 12.2.1.2. Overview
- 12.2.1.3. Financial (Subject to Data Availability)
- 12.2.1.4. Product Summary
- 12.2.1.5. Recent Developments
- 12.2.2. Mylan N.V. (U.S.)
- 12.2.3. Teva Pharmaceutical Industries Ltd. (Israel)
- 12.2.4. Sanofi (France)
- 12.2.5. Pfizer Inc. (U.S.)
- 12.2.6. GlaxoSmithKline plc (U.K.)
- 12.2.7. Novartis AG (Switzerland)
- 12.2.8. AstraZeneca (U.K.)
- 12.2.9. Johnson & Johnson (U.S.)
- 12.2.10. Bayer AG (Germany)
Chapter 13. Research Process
- 13.1. Research Process
- 13.1.1. Data Mining
- 13.1.2. Analysis
- 13.1.3. Market Estimation
- 13.1.4. Validation
- 13.1.5. Publishing
- 13.2. Research Attributes
- 13.3. Research Assumption